Division of Evidence-Based Medicine, Department of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
JAMA Dermatol. 2019 Jun 1;155(6):730-732. doi: 10.1001/jamadermatol.2019.0279.
Is the use of ivermectin in patients infested with scabies associated with improved clinical and safety outcomes compared with permethrin?
Both ivermectin and permethrin treatment were associated with high clearance rates. There is low-certainty evidence that ivermectin was associated with slightly lower rates of complete clearance after 1 week compared with permethrin, 5%, cream (relative risk [RR], 0.65; 95% CI, 0.54-0.78). After 2 weeks, there was no difference in efficacy (RR, 0.91; 95% CI, 0.76-1.08; low-certainty evidence), or in the number of participants with adverse events (week 4: RR, 1.30; 95% CI, 0.35-4.83; low-certainty evidence).
与扑灭司林相比，用于治疗疥疮感染的伊维菌素是否能改善临床和安全性结局？
伊维菌素和扑灭司林治疗均与高清除率相关。有低确定性证据表明，与扑灭司林相比，伊维菌素在第 1 周后完全清除的比例略低，为 5%（乳膏）（相对风险 [RR]，0.65；95%置信区间 [CI]，0.54-0.78）。第 2 周时，疗效无差异（RR，0.91；95%CI，0.76-1.08；低确定性证据），或不良事件参与者人数无差异（第 4 周：RR，1.30；95%CI，0.35-4.83；低确定性证据）。
